A Phase 1, Randomised, Double Blind Placebo-controlled, First Time in Human Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Oral Doses and Food Effect of GSK4024484 in Healthy Adult Participants
Latest Information Update: 29 Feb 2024
At a glance
- Drugs GSK 4024484 (Primary)
- Indications Malaria
- Focus Adverse reactions; First in man
- Sponsors GSK
Most Recent Events
- 22 Feb 2024 Status changed from not yet recruiting to recruiting.
- 21 Dec 2023 New trial record